Seres Therapeutics (MCRB) Equity Average (2016 - 2025)
Historic Equity Average for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $38.3 million.
- Seres Therapeutics' Equity Average rose 22136.33% to $38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.3 million, marking a year-over-year increase of 22136.33%. This contributed to the annual value of -$15.5 million for FY2024, which is 880.76% up from last year.
- Per Seres Therapeutics' latest filing, its Equity Average stood at $38.3 million for Q3 2025, which was up 22136.33% from $41.7 million recorded in Q2 2025.
- Seres Therapeutics' 5-year Equity Average high stood at $159.2 million for Q1 2021, and its period low was -$73.4 million during Q2 2024.
- In the last 5 years, Seres Therapeutics' Equity Average had a median value of $38.3 million in 2025 and averaged $38.6 million.
- As far as peak fluctuations go, Seres Therapeutics' Equity Average surged by 38957.56% in 2021, and later crashed by 94307.84% in 2024.
- Over the past 5 years, Seres Therapeutics' Equity Average (Quarter) stood at $153.6 million in 2021, then plummeted by 74.49% to $39.2 million in 2022, then plummeted by 176.54% to -$30.0 million in 2023, then soared by 162.86% to $18.9 million in 2024, then surged by 103.29% to $38.3 million in 2025.
- Its last three reported values are $38.3 million in Q3 2025, $41.7 million for Q2 2025, and $32.1 million during Q1 2025.